Abstract
In chronic inflammation, across a number of quite different pathological conditions, monocytes accumulate. In autoimmune disease, these cells are widely recognised to play an inflammatory and tissue destructive role. But these cells also inhibit T cell proliferation by a range of different mechanisms that are accompanied by the depletion of specific amino acids in the local microenvironment and the downregulation of the T cell receptor ζ chain. This occurs within the pro-inflammatory environment and in the presence of Th1 (IFNγ) and Th17 (IL-17) cytokines. In tumours, related cells are part of a population called myeloid-derived suppressor cells (MDSC) and they are associated with immunosuppression. Their depletion can lead to clinical improvement. In organ specific autoimmune disease, where such cells can be found in the spleen and in target organs, recent evidence indicates that they may play a role in limiting the T cell response to autoantigens in the target tissue. This occurs by a targeted disruption of T cell division. In this review we discuss evidence for the presence on MDSC in murine and human autoimmune disease and the mechanisms by which such cells inhibit T cell proliferation.
Keywords: MDSC, monocyte, macrophage, autoimmune disease, EAE, EAU
Current Molecular Medicine
Title: Monocyte Dependent Regulation of Autoimmune Inflammation
Volume: 9 Issue: 1
Author(s): Lindsay B. Nicholson, Ben J.E. Raveney and Markus Munder
Affiliation:
Keywords: MDSC, monocyte, macrophage, autoimmune disease, EAE, EAU
Abstract: In chronic inflammation, across a number of quite different pathological conditions, monocytes accumulate. In autoimmune disease, these cells are widely recognised to play an inflammatory and tissue destructive role. But these cells also inhibit T cell proliferation by a range of different mechanisms that are accompanied by the depletion of specific amino acids in the local microenvironment and the downregulation of the T cell receptor ζ chain. This occurs within the pro-inflammatory environment and in the presence of Th1 (IFNγ) and Th17 (IL-17) cytokines. In tumours, related cells are part of a population called myeloid-derived suppressor cells (MDSC) and they are associated with immunosuppression. Their depletion can lead to clinical improvement. In organ specific autoimmune disease, where such cells can be found in the spleen and in target organs, recent evidence indicates that they may play a role in limiting the T cell response to autoantigens in the target tissue. This occurs by a targeted disruption of T cell division. In this review we discuss evidence for the presence on MDSC in murine and human autoimmune disease and the mechanisms by which such cells inhibit T cell proliferation.
Export Options
About this article
Cite this article as:
Nicholson B. Lindsay, Raveney J.E. Ben and Munder Markus, Monocyte Dependent Regulation of Autoimmune Inflammation, Current Molecular Medicine 2009; 9 (1) . https://dx.doi.org/10.2174/156652409787314499
DOI https://dx.doi.org/10.2174/156652409787314499 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic and Pharmacological Modulation of Dendritic Cell-T Cell Interactions as a Therapeutic Strategy for Systemic Lupus Erythematosus
Current Gene Therapy Dendritic Cells and Immunomodulation: Role in Health and Disease
Current Immunology Reviews (Discontinued) Control of Autoimmune Diseases by the B7-CD28 Family Molecules
Current Pharmaceutical Design Update on ICOS: A Possible Target for Turning-Off Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Editorial [Hot Topic: Innate Immunity and Autoimmune Disease (Guest Editors: F. Susan Wong and Li Wen)]
Current Molecular Medicine Chronic Immune Stimulation Correlates with Reduced Phenylalanine Turnover
Current Drug Metabolism Immunopathology of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry Editorial (Thematic Issues: Heads Or Tails: Betting On CD6 As a Resurged Target For Autoimmune Diseases and Sepsis)
Current Drug Targets Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease
Current Stem Cell Research & Therapy Anti-CCP Antibody Detection Facilitates Early Diagnosis and Prognosis of Rheumatoid Arthritis
Current Rheumatology Reviews Immuno - Functionalized Silver Nanoparticles for Diagnostics, Therapeutics and Protection of Rabies Viral Infection
Current Nanomedicine New Analytical Tools for Studying Autoimmune Diseases
Current Pharmaceutical Design Ganglioside Mimicry as a Cause of Guillain-Barre Syndrome
CNS & Neurological Disorders - Drug Targets To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets The Role of Neutrophil Proteases in LPS-Induced Production of Regulatory Rheumatoid Factor that Suppresses Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets Lipid-Based Nanocarriers for RNA Delivery
Current Pharmaceutical Design HMGB-1 as a Target for Inflammation Controlling
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases
Central Nervous System Agents in Medicinal Chemistry Migraine in Systemic Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets